Xencor appoints Nancy Valente as EVP, Chief Development Officer; board reduced to 7

Xencor Inc

Nancy Valente appointed EVP and Chief Development Officer effective May 1, 2023; she resigned from board.
Valente previously SVP at Genentech/Roche; led development of GAZYVA, VENCLEXTA, POLIVY, HEMLIBRA.
Compensation: $540K base salary, 50% bonus target, option grant for 235,778 shares ($3.9M), RSU grant of 39,269 shares ($1.3M).
Allen Yang steps down as executive officer effective May 1 but stays in non-executive role.
Board size reduced from 8 to 7 to eliminate vacant seat left by Valente.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nancy Valente

Director

XNCR · Xencor Inc

Effective: 2023-05-01
Filed: April 26, 2023, 7:59 PM ET

Dr. Nancy Valente tendered her offer of resignation from the Board of Directors (the "Board") of Xencor, Inc. (the "Company"), subject to the Board's acceptance of her resignation. Also on April 24, 2023, the Board accepted Dr. Valente's resignation, effective as of May 1, 2023.

Role change

Allen Yang

executive officer

XNCR · Xencor Inc

Effective: 2023-05-01
Filed: April 26, 2023, 7:59 PM ET

Dr. Allen Yang will step down from his role as an executive officer of the Company. He will continue to be employed by the Company in a non-executive capacity.

Appointed

Nancy Valente

Executive Vice President and Chief Development Officer

XNCR · Xencor Inc

Effective: 2023-05-01
Filed: April 26, 2023, 7:59 PM ET

Dr. Nancy Valente, age 64, was appointed as Executive Vice President and Chief Development Officer of the Company, effective May 1, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy Valente resigned as Director at Xencor Inc.

Action: resigned
Role: Director

Exact text from the filing

Dr. Nancy Valente tendered her offer of resignation from the Board of Directors (the "Board") of Xencor, Inc. (the "Company"), subject to the Board's acceptance of her resignation. Also on April 24, 2023, the Board accepted Dr. Valente's resignation, effective as of May 1, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Allen Yang changed role as executive officer at Xencor Inc.

Action: stepped down
Role: executive officer

Exact text from the filing

Dr. Allen Yang will step down from his role as an executive officer of the Company. He will continue to be employed by the Company in a non-executive capacity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy Valente was appointed as Executive Vice President and Chief Development Officer at Xencor Inc.

Action: appointed
Role: Executive Vice President and Chief Development Officer

Exact text from the filing

Dr. Nancy Valente, age 64, was appointed as Executive Vice President and Chief Development Officer of the Company, effective May 1, 2023

View on SEC.gov

Xencor Inc filing history →

Source: SEC EDGAR

accession 0001628280-23-013066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.